BIOGEN o

PHARMACHEM INDUSTRIES LIMITED

ClN NO : L51100GJ1995PLC026702 (Formerly Known as SUN TECHNO OVERSEAS LIMITED)

Dat e: 13.02.2024

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir / Madam,

Sub: Un-Audited Financial Result quarter ended on 31 st December 2023 pursuant to

Regulation 33 of the SEBI (lODR) Regulations, 2015.

Pursuant to Second proviso to Regulation 30(6) and Regu lation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 we hereby inform you that we have submitted quarterly
financial results as on Monday 22 nd January 2024. However, query received from the BSE exchange
regarding signing of financial results. But the results were already signed by Wholetime Director but due
to typing mistake it was written only director instead of Wholetime Director. So here we are submitting
the same again and there is no change in the financial results for the quarter ended as on 31.12.2023.

The meeting commenced at 03.4s.P.M. and concluded at 04.1S.P.M.

Kindly take the same on your record and oblige.

Thanking You

Yours Faithfully,
FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED
...

Narendra V niya
Director

R.gi ....... OlRc. A ......... Shop No••, Fl... Floo., Malte•• - , Bull"lng, ,awaha. R_", Ralllot-16000'
Email biogenpharmachem@gmail.com
 BIOGEN PHARMACHEM INDUSTRIES LIMITED
CI :- L659 10GJ I995PLC026702
Regd . Office: Shop No.8, First Floor, Make rs - I Building, Jawahar Road , Rajkot - 36000 I
Emai l:- suntechn ooverseas(iilgmail.com
Statement of Unaudi ted f inancial Results fo r the Quarter Ended December 31, 2023
R" In lar,)
SI Particulars Q ua rter Ended Quarter Ended Quarter Ended Ni ne Monts Nine Monts
Vear Ended 3 1
No, 31 Dec'2023 30 Sept'2023 31Dec'2022 Ended 31 En ded 31
Mar 2023
Dec'2023 Dec'2022
(Refer Notes Below) (Unaudited) (Unaudited) (Unaud ited) (Unaudited) (Unaudited) (Audited)
I In come
(a) Revenue from Operations -
(b) Other Income 9.24 75.67 32.50 160.22 83.83 91.28
Tota l In come from Operations (Net) 9.24 75.67 32.50 160.22 83.83 91.28
2 Expenses
(a) Cost of materia l consumed
(b) Purchase of stock in trade
(c) Changes in inventories of finished goods, work-in-progress, and stock-
in-trade -
(d) Employee benefit expense 0.94 0.52 0.48 6.94 1.97 17.45
(e) Finance Costs -
(I) Depreciation and A11l01tization Expense
(g) Other expenses 2.07 3.12 1. 89 34.35 16.63 28.28 I
Total Ex penses 3.01 3.64 2.37 41.29 18.60 45.73
3 Profit I (Loss) from operations before exceptiona l items and Tax (I-
6.23 72.03 30.13 11 8.94 65.23 45.55
2)
4 Exceptional Items -
5 Profit I (Loss) before Tax (3 ± 4) 6.23 72.03 30. 13 118.94 65.23 45.55
6 Tax Expense -
7 Profit I (Loss) after tax (5 - 6) 6.23 72.03 30.13 118.94 65.23 45.55
8 Other co mprehensive income (Net of Tax)
A. (i) Items U,at will not be reclassified to profit or loss -
(ii) Income tax relating to items that will not be reclassified profit or -
B. (i) Items that will be reclassified to Profit or Loss -
9 Tota l co mprehensive income (7 ± 8) 6.23 72.03 30.13 118.94 65.23 45.55
to Paid-up equi ty share capital (Face Value of Rs . I/- each) 6,526.03 6,526.03 6,526.03
6,526.03 6,526.03 6,526.03
II Other Equity ( 1,067.06)
12 E.rni ngs Pcr S ha re (before extroordin ary items) (of Rs.11- eac h)
(not a nnu alised):
a) Basic 0.00 0.01 0.00 0.02 0.01 0.01
I(b) Diluted 0.00 0.0 1 0.00 0.02 0.01 0.01

Notes:
I
The above financial results have been reviewed by the Audit Comm ittee and approved by the Board of Directors at its meeting held on January 22, 2024. The Statutory Auditors have carried
out a limited review of the above financial result.
2 Company has only one segment and hence no separate segment resuh has been given.
3 The figure of previous period/year have been re·grouped I re·arranged and lor recast wherever found necessary.
~

~
4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of th.,.S ard

Q::'
~~
~Ia
I ~
~
Place : Rajkot
Date : 22nd January, 2024
~......: WhOIC.!\, • ~r ctor

-
 RISHI SEKHRI AND ASSOCIATES
CHARTERED ACCOUNTANTS
GROUND FLOOR BANDRAARCADE BUILDING, OPP. RAILWAY STATION,. BANDRA (WEST), MUMBAI - 400 050.
, , Tel. : 9820501848, Email : rishisekhri@gmall.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited
Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI
Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended
To
The Boa rd of Directors of
Biogen Pharmachem Industries Limited
•
We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Biogen
Pharmachem Industries Limited("the Company"), for the Quarter ended on December 31, 2023 and year to
date result for the period from 01 April, 2023 to 31 December, 2023 ("the Statement"), being submitted by
the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The Company's Management is responsible for the preparation of the Statement in accordance with the
recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim
Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with
relevant rules issued thereunder and ot~~r acco unting principles generally accepted in India and in
compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the
Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our
review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)
2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued
by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the
review to obtain moderate assurance as to whether the Statement is free of material misstatement A review
of interim financia l information consists of making inquiries, primarily of persons responsible for fin ancial
and accounting matters, and applying analytical and other review procedures. A review is substantially less in
scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable
us to obtain assurance that we would become aware of all significant matters that might be identified in an
audit. Accordingly, we do not express an audit opinion.
'"
Based on our review conducted as above, nothing has come to our attention that causes us to believe that the
accom panying Statement, prepared in accordance with the recognition and measurement principles laid
down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies
Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally
accepted in India, has not disclosed the information required to be disclosed in terms of the Listing
Regulations, including the man ner in which it is to be disclosed, or that it contains any material misstatement

FOR, RISHI SEKHRI AND ASSOCIATES,

artered ACCO
U ntants
Il
R ,,1 2 16W
,
SHI KHRI
Partner
MEM B~EgR\SHW1'1lf..11l26656

Place: MUMBAI
Date: 22.01.2024
UDIN,24126656BGWLOP6568